Rhythm Pharmaceuticals, Inc. acquired the target/assets from HealthCare Royalty Partners in a revenue interest financing on 2022-06-17.
Deal value was 1000000000 (source: Extracted) Sector: Biopharmaceuticals; Location: USA.
On the acquirer side, Latham & Watkins advised, led by Haim Zaltzman, Pete Handrinos, Dan Van Fleet.
Generated by AI, original source from - Data is in progress
Rhythm Pharmaceuticals, Inc. advisor
Firm name is in progress
Found it useful? Spread the word.
Latham & Watkins advises Rhythm Pharmaceuticals in US$100 million revenue interest financing with HealthCare Royalty Partners | The Sponsor - The Sponsor
